{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Centessa Pharmaceuticals plc"},"Symbol":{"label":"Symbol","value":"CNTA"},"Address":{"label":"Address","value":"1 ASHLEY ROAD,3RD FLOOR, CHESHIRE, WA14 2DT, United Kingdom"},"Phone":{"label":"Phone","value":"+44 2039206789"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Europe"},"CompanyDescription":{"label":"Company Description","value":"Centessa Pharmaceuticals PLC is a pharmaceutical company. Its portfolio consists of preclinical to phase 3 uncorrelated programs spanning diseases with high unmet need across oncology, hematology, immunology, inflammation, neuroscience, and rare diseases. Some of its products include Vasopressin V2 Receptor Inhibitor (Lixivaptan), BMP9 Engineered Variant (MGX292), OX2R Agonist (Oral) among others."},"CompanyUrl":{"label":"Company Url","value":"https://www.centessa.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"April Dovholuk","title":"Senior Vice President-Operations Development"},{"name":"Ellie Im","title":"Senior VP-Oncology Clinical Development"},{"name":"Saurabh Saha","title":"Chief Executive Officer & Director"},{"name":"Tia Bush","title":"Chief Technology and Quality Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}